Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.20%
#2 aelf aelf +23.74%
#3 Bitway Bitway +16.31%
#4 Decred Decred +11.24%
#5 TRIA TRIA +8.49%
#6 Wibx Wibx +8.11%
#7 Pons Pons +7.97%
#8 DexNet DexNet +7.55%
#9 Status Status +7.12%
#10 AtomOne AtomOne +7.07%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Perseus Proteomics Inc. Perseus Proteomics Inc.

Perseus Proteomics Inc.

4882
Rank in Stocks #30380
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology... Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Share Price
$0.93298493
Market Cap
$17.19M
Change (1 day)
-1.38%
Change (1 year)
-62.47%
Country
JP
Trade Perseus Proteomics Inc. (4882)

Category

Healthcare
Revenue for Perseus Proteomics Inc. (4882)
Revenue in Aug 2026 TTM: 0
According to Perseus Proteomics Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Perseus Proteomics Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $79.67B -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $97.93B -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $64.39B -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $77.52B -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $66.40B -
US